VSBC on OTC
VITASPRING BIOMEDICAL CO. LTD.
American commercial physical and biological research services company1
In its 2026 annual report the company says: “We are a development-stage biomedical company engaged in the research, development, and commercialization of products that promote wellness and a healthy lifestyle.”4 It is headquartered in Riverside, California.1 Its shares trade on OTC under the symbol VSBC.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with bioAffinity Technologies, Inc., Absci Corp or iSpecimen Inc., or pick any stock.
- TickerVSBC on OTC1
- IndustryServices-Commercial Physical & Biological Research1
- HeadquartersRiverside, California1
- Incorporated inNV3
- Business address5225 Canyon Crest Dr., Ste 71-825, Riverside, Ca 925073
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
These statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions, and are subject to known and unknown risks, uncertainties, and factors that could cause actual results to differ materially from those expressed or implied. Important factors that could cause such differences include, but are not limited to:4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-01-31 | 2025-01-31 |
|---|---|---|
| Revenues | $0 | $0 |
| Cost of goods sold | $0 | $0 |
| Gross profit | $0 | $0 |
| Selling, general and administrative expenses | $385.4K | $679.9K |
| Loss from operations | -$385.4K | -$679.9K |
| Net loss from operations before provision for income taxes | -$385.4K | -$679.9K |
| Provision for income tax expense | -$30.0K | -$95.0K |
| Net loss | -$415.4K | -$774.9K |
| Net loss per share: Basic and diluted | $0.00 | $0.00 |
| Weighted average number of shares outstanding: Basic and diluted | 207.0M shares | 207.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-01-31 | 2025-01-31 | 2024-01-31 |
|---|---|---|---|
| Cash | $2.1K | $272 | $13 |
| Prepaid expenses | $8.4K | $0 | |
| Total current assets | $10.5K | $272 | |
| Equipment and vehicle, net | $4.1K | $14.1K | |
| Total long-term asset | $4.1K | $14.1K | |
| Total assets | $14.7K | $14.4K | |
| Accounts payable - related party | $2.4M | $2.4M | |
| Accounts payable and other payables | $652.0K | $494.8K | |
| Income tax payable | $344.2K | $313.7K | |
| Advances from related party | $1.0M | $810.1K | |
| Total current liabilities | $4.4M | $4.0M | |
| Total liabilities | $4.4M | $4.0M | |
| COMMITMENTS AND CONTINGENCIES | $0 | $0 | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized 207,030,030 shares issued and outstanding. | $20.7K | $20.7K | |
| Additional paid-in capital | $1.2M | $1.2M | |
| Accumulated deficit | -$5.7M | $5.3M | |
| Total stockholders' deficit | -$4.4M | -$4.0M | |
| Total liabilities and stockholders' deficit | $14.7K | $14.4K | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 207.0M shares | 207.0M shares | |
| Common stock, shares outstanding | 207.0M shares | 207.0M shares |
| Period ending | 2026-01-31 | 2025-01-31 | 2024-01-31 |
|---|---|---|---|
| Cash | $2.1K | $272 | $13 |
| Prepaid expenses | $8.4K | $0 | |
| Total current assets | $10.5K | $272 | |
| Equipment and vehicle, net | $4.1K | $14.1K | |
| Total long-term asset | $4.1K | $14.1K | |
| Total assets | $14.7K | $14.4K | |
| Accounts payable - related party | $2.4M | $2.4M | |
| Accounts payable and other payables | $652.0K | $494.8K | |
| Income tax payable | $344.2K | $313.7K | |
| Advances from related party | $1.0M | $810.1K | |
| Total current liabilities | $4.4M | $4.0M | |
| Total liabilities | $4.4M | $4.0M | |
| COMMITMENTS AND CONTINGENCIES | $0 | $0 | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized 207,030,030 shares issued and outstanding. | $20.7K | $20.7K | |
| Additional paid-in capital | $1.2M | $1.2M | |
| Accumulated deficit | -$5.7M | $5.3M | |
| Total stockholders' deficit | -$4.4M | -$4.0M | |
| Total liabilities and stockholders' deficit | $14.7K | $14.4K | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 207.0M shares | 207.0M shares | |
| Common stock, shares outstanding | 207.0M shares | 207.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-01-31 | 2025-01-31 |
|---|---|---|
| Net loss | -$415.4K | -$774.9K |
| Depreciation expense | $10.0K | $10.0K |
| Non-cash lease expense | $0 | $89.7K |
| Stock-based compensation | $0 | $109.9K |
| Prepaid expenses | -$8.4K | $0 |
| Deposits | $0 | $23.6K |
| Accounts payable and other payables | $157.3K | $155.8K |
| Change in operating lease liability | $0 | -$93.3K |
| Income tax and franchise tax expenses | $30.5K | $95.0K |
| Advances from related party for operating expenses | $223.4K | $369.7K |
| Net cash used in operating activities | -$2.7K | -$14.7K |
| Advances from related party | $4.5K | $14.9K |
| Net cash provided by financing activity | $4.5K | $14.9K |
| Net change in cash | $1.8K | $259 |
| Income taxes paid | $0 | $0 |
| Interest expense paid | $0 | $0 |
| Stock-based compensation for restricted common shares | $0 | $109.9K |
No quarter-by-quarter statement was filed.
What it owns
What VITASPRING BIOMEDICAL CO. LTD. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $73.0K2 Jan 31, 2026 | $73.0K2 Jan 31, 2025 | 0% |
| Accumulated depreciation | $58.4K2 Jan 31, 2026 | $48.4K2 Jan 31, 2025 | +20.6% |
| Property and equipment, net | $4.1K2 Jan 31, 2026 | $14.1K2 Jan 31, 2025 | −70.6% |
| Operating-lease assets (leased space) | $02 Jan 31, 2026 | $02 Jan 31, 2025 |
Investments
Properties, in its own words
We do not own any real property and currently lease our offices located at 5225 Canyon Crest Drive, Suite 71-825, Riverside, CA 92507. Our lease is for a virtual office space, and our rent is $33 per month. Our telephone number is (949) 202-9235. During fiscal year 2024 and 2023, we maintained a branch office located at 1F., No. 95, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan, where the former management team operated. From August 2021 to July 2024, we maintained our principal executive offices at 400 Spectrum Center Dr., Suite 1620, Irvine, CA 92618. In May 2025, we relocated to our current address, which serves as our current executive office as of the date of this report.
Item 2 of the 10-K filed Jun 17, 2026.4
Former names
- Shemn Corp.Mar 6, 2017 to Apr 27, 20203
Timeline
Filings
29 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 5 major events, 4 other. The latest 20:
- Sep 17, 202610-Q EDGAR
- Sep 15, 2026NT 10-Q EDGAR
- Sep 10, 20268-K EDGAR
- Jun 17, 202610-Q EDGAR
- Jun 17, 202610-K EDGAR
- Jun 17, 202610-Q EDGAR
- Jun 17, 202610-Q EDGAR
- Jun 15, 202610-Q EDGAR
- Jun 8, 202610-K EDGAR
- May 6, 202610-Q EDGAR
- Apr 22, 202610-Q EDGAR
- Apr 2, 202610-Q EDGAR
- Mar 12, 202610-K EDGAR
- Jan 30, 202610-Q EDGAR
- Jan 23, 202610-Q EDGAR
- Jan 13, 202610-Q EDGAR
- Dec 1, 202510-K EDGAR
- Aug 25, 20258-K EDGAR
- Aug 11, 20258-K CURRENT REPORT EDGAR
- Jul 29, 20258-K CURRENT REPORT EDGAR
The 29 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How VITASPRING BIOMEDICAL CO. LTD. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARVITASPRING BIOMEDICAL CO. LTD.1
- CIK0001697884
- Employer ID (EIN)37-18367264
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inNevada4
- Fiscal year endsJanuary 311
- Industry code (SIC)8731 Services-Commercial Physical & Biological Research1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address5225 Canyon Crest Dr., Ste 71-825, Riverside, CA 925071
- Phone94920292351
- Shares outstanding207,030,030 as of Sep 14, 202613
- Public float$0 as of Jul 31, 20252
- AuditorJP CENTURION & PARTNERS PLT, Kuala Lumpur, Malaysia PCAOB ID 6723; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMar 6, 20171
- Filings74 in all: 10-Q (29), 8-K (14), 10-K (9), NT 10-Q (5), S-1/A (5), UPLOAD (4), NT 10-K (3), 8-K/A (2)1
All 11 form types
CORRESP (1), EFFECT (1), S-1 (1)
- Latest filingsAnnual report (10-K) Jun 17, 2026
Quarterly report (10-Q) Sep 17, 2026
Latest 8-K (8-K) Sep 10, 2026
Risk factors and legal proceedings
The risks VITASPRING BIOMEDICAL CO. LTD. names in Item 1A of its 10-K filed Jun 17, 2026: 25 risks under these headings, as written.4
- RISKS RELATED TO OUR FINANCIAL CONDITION, LIQUIDITY AND GOING CONCERN
- Substantial doubt exists regarding our ability to continue as a going concern.
- Our liabilities substantially exceed our assets, which may impair our ability to obtain financing and satisfy uplisting requirements.
- We may not be able to satisfy our obligations as they become due.
- RISKS RELATED TO OUR DEVELOPMENT-STAGE STATUS AND BUSINESS STRATEGY
- We have not commenced commercial operations and have no history of revenue generation.
- Our business model is speculative and subject to significant execution risk.
- We may change our business strategy.
- RISKS RELATED TO REGULATORY MATTERS
- If we pursue regenerative medicine or biologic-based products, we will be subject to extensive regulatory requirements.
- Failure to obtain or maintain regulatory approvals would prevent commercialization.
- The regulatory landscape for stem-cell and exosome technologies is evolving.
The other 16 risks
- RISKS RELATED TO INTELLECTUAL PROPERTY
- We do not currently hold issued patents.
- We may become involved in intellectual property disputes.
- RISKS RELATED TO RELATED-PARTY TRANSACTIONS AND CONFLICTS OF INTEREST
- We have significant obligations to related parties, including a former officer who is involved in criminal proceedings unrelated to us.
- Our governance structure may increase conflict-of-interest risk.
- RISKS RELATED TO FORMER MANAGEMENT AND LEGAL PROCEEDINGS
- Former officers are involved in civil and criminal proceedings that could indirectly affect us.
- We may be subject to litigation.
- RISKS RELATED TO INTERNAL CONTROL OVER FINANCIAL REPORTING
- We have identified a material weakness in internal control over financial reporting.
- RISKS RELATED TO CAPITAL RAISING AND DILUTION
- We will require substantial additional capital to execute our business strategy.
- Future issuances of securities may dilute existing stockholders and depress our stock price.
- Our net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code, which could reduce or eliminate their value.
- RISKS RELATED TO UPLISTING AND MARKET STATUS
- Because we currently have a stockholders’ deficit and lack independent directors, we may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.
- Our common stock is thinly traded and may experience significant volatility.
- Our common stock may be subject to penny stock regulations.
- RISKS RELATED TO CYBERSECURITY AND DATA PROTECTION
- We do not maintain a formal cybersecurity risk management framework.
- GENERAL RISK FACTORS
- Economic conditions may adversely affect our ability to raise capital.
- We may become subject to securities class action litigation or stockholder derivative actions, which could result in substantial costs and diversion of management attention.
Legal proceedings
From time to time, we may be involved in routine litigation incidental to the conduct of our business. We are not currently involved in any legal proceedings, and we are not aware of any pending or potential legal actions against us.
As previously disclosed in our Company’s Form 10-K for the fiscal year ended January 31, 2023, and in our Report on Form 8-K filed August 11, 2025, certain of our former officers are involved in civil and criminal proceedings in Taiwan relating to alleged unauthorized use of proprietary know-how and intellectual property. We are not a named party to these proceedings. Please refer to the Form 8-K for additional information regarding those matters.
As of January 31, 2026, and through the date of issuance of these financial statements, management is not aware of any developments that would cause us to conclude that these matters will have a material adverse effect on our financial condition or results of operations.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARExecutive or director change
- 15SEC EDGARChange of auditor
- 16
- 17
- 18SEC EDGARChange of auditor